About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker NUVB · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 10, 2026Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued V…
NCT07703436 · Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma
Safusidenib
NUVB
Nuvation Bio Inc.
Phase 2Recruiting40Sep 2030Registry ↗
Oct 19, 2026SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519 · Glioma, Astrocytoma, Grade IV
safusidenib, Placebo
NUVB
Nuvation Bio Inc.
Phase 3Recruiting365Dec 1, 2028Registry ↗
Aug 3, 2026Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib
NCT07742384 · Healthy Adult Participants
Taletrectinib, Taletrectinib, Famotidine
NUVB
Nuvation Bio Inc.
Phase 1Not yet recruiting56Feb 2, 2027Registry ↗
Jul 17, 2026Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma
NCT07712757 · Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an I…
Safusidenib, Placebo
NUVB
Nuvation Bio Inc.
Phase 3Not yet recruiting140May 2029Registry ↗
May 19, 2026Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
NCT07154706 · Non-small Cell Lung Cancer (NSCLC)
Taletrectinib, Placebo
NUVB
Nuvation Bio Inc.
Phase 3Recruiting180Aug 30, 2030Registry ↗
Apr 13, 2026A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced o…
NCT06564324 · Non Small Cell Lung Cancer
Taletrectinib, Crizotinib
NUVB
Nuvation Bio Inc.
Phase 3Recruiting194Jan 2029Registry ↗
Feb 6, 2026A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
NCT04395677 · Non Small Cell Lung Cancer
AB-106
NUVB
Nuvation Bio Inc.
Phase 2Active, not recruiting173Jun 7, 2024Registry ↗
Jan 21, 2026Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
NCT04617054 · Solid Tumor
AB-106
NUVB
Nuvation Bio Inc.
Phase 2Terminated14Dec 6, 2024Registry ↗
Jan 14, 2026Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432 · Advanced Solid Tumor, HER2-negative Breast Cancer
NUV-1511
NUVB
Nuvation Bio Inc.
Phase 1/2Active, not recruiting466Mar 2027Registry ↗
Jan 7, 2026Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811 · Non Small Cell Lung Cancer
Taletrectinib
NUVB
Nuvation Bio Inc.
Phase 2Active, not recruiting217Jun 11, 2025Registry ↗
Dec 24, 2025Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC
NCT06841874 · Lung Neoplasms, Respiratory Tract Neoplasms
Taletrectinib
NUVB
Nuvation Bio Inc.
—No longer available——Registry ↗
Nov 6, 2025NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Adva…
NCT05252390 · Advanced Solid Tumor, Ovarian Cancer
NUV-868, Olaparib
NUVB
Nuvation Bio Inc.
Phase 1Terminated82Jul 15, 2024Registry ↗
Jun 24, 2025A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
NCT02279433 · Solid Tumors
DS6051b
NUVB
Nuvation Bio Inc.
Phase 1Completed46Mar 2019Registry ↗
Nov 21, 2024Study the Effect of Omeprazole on AB-106 Pharmacokinetics
NCT05609929 · Pharmacokinetic Study
Multiple administration of omeprazole Single administration…
NUVB
Nuvation Bio Inc.
Phase 1Completed24Jan 20, 2023Registry ↗
Nov 21, 2024A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin
NCT05357911 · Solid Tumor
AB-106, digoxin
NUVB
Nuvation Bio Inc.
Phase 1Completed16Aug 20, 2021Registry ↗
Nov 21, 2024A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin…
NCT05357820 · Solid Tumor
AB-106, Itraconazole, AB-106, Rifampicin
NUVB
Nuvation Bio Inc.
Phase 1Completed56Dec 3, 2021Registry ↗
Jul 14, 2023Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
NCT04541225 · Glioma, Glioma, Malignant
NUV-422
NUVB
Nuvation Bio Inc.
Phase 1Terminated74Aug 31, 2022Registry ↗
Jul 11, 2023Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
NCT05191004 · Advanced Breast Cancer, Metastatic Breast Cancer
NUV-422, Fulvestrant
NUVB
Nuvation Bio Inc.
Phase 1/2Withdrawn0Jun 2025Registry ↗
Aug 5, 2022Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
NCT05191017 · Prostate Cancer, Prostatic Cancer
NUV-422, Enzalutamide
NUVB
Nuvation Bio Inc.
Phase 1/2Withdrawn0Jan 2025Registry ↗

19 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:54 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances